Tenax Therapeutics gained over 47% on Wednesday after it announced that it had a productive pre-Investigational New Drug (pre-IND) meeting with the FDA for a phase II study of Levosimendan in Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF).
Original Article: TENX Heartened After Meeting With FDA, RXII To Report Data In May, GALT On Watch